MPP Announces Generic Paxlovid Licences For LMICs
Generics Of Pfizer’s Oral COVID-19 Treatment Will Be Supplied To 95 Countries
Executive Summary
A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.
You may also be interested in...
Challenges Remain For Off-Patent Industry’s COVID Response
At an symposium convened by the WHO, WIPO and WTO, the IGBA has highlighted ongoing challenges for the off-patent industry’s continuing response to the COVID-19 pandemic.
MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”
MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”